<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37463793</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>Predictors of British Isles Lupus Assessment Group-based outcomes in patients with systemic lupus erythematosus: Analysis from the Systemic Lupus International Collaborating Clinics Inception Cohort.</ArticleTitle><Pagination><StartPage>1043</StartPage><EndPage>1055</EndPage><MedlinePgn>1043-1055</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09612033231183273</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We aimed to identify factors associated with a significant reduction in SLE disease activity over 12&#xa0;months assessed by the BILAG Index.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In an international SLE cohort, we studied patients from their 'inception enrolment' visit. We also defined an 'active disease' cohort of patients who had active disease similar to that needed for enrolment into clinical trials. Outcomes at 12&#xa0;months were; Major Clinical Response (MCR: reduction to classic BILAG C in all domains, steroid dose of &#x2264;7.5&#xa0;mg and SLEDAI &#x2264; 4) and 'Improvement' (reduction to &#x2264;1B score in previously active organs; no new BILAG A/B; stable or reduced steroid dose; no increase in SLEDAI). Univariate and multivariate logistic regression with Least Absolute Shrinkage and Selection Operator (LASSO) and cross-validation in randomly split samples were used to build prediction models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">'Inception enrolment' (<i>n</i> = 1492) and 'active disease' (<i>n</i> = 924) patients were studied. Models for MCR performed well (ROC AUC = .777 and .732 in the inception enrolment and active disease cohorts, respectively). Models for Improvement performed poorly (ROC AUC = .574 in the active disease cohort). MCR in both cohorts was associated with anti-malarial use and inversely associated with active disease at baseline (BILAG or SLEDAI) scores, BILAG haematological A/B scores, higher steroid dose and immunosuppressive use.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Baseline predictors of response in SLE can help identify patients in clinic who are less likely to respond to standard therapy. They are also important as stratification factors when designing clinical trials in order to better standardize overall usual care response rates.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>David</LastName><ForeName>Trixy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>The Kellgren Centre for Rheumatology, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.</Affiliation><Identifier Source="RINGGOLD">5293</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>MRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK.</Affiliation><Identifier Source="RINGGOLD">12204</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Yafeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>MRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK.</Affiliation><Identifier Source="RINGGOLD">12204</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1244-6443</Identifier><AffiliationInfo><Affiliation>Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.</Affiliation><Identifier Source="RINGGOLD">1724</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The Kellgren Centre for Rheumatology, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.</Affiliation><Identifier Source="RINGGOLD">5293</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isenberg</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-9514-2455</Identifier><AffiliationInfo><Affiliation>Centre for Rheumatology, Division of Medicine, University College London, London, UK.</Affiliation><Identifier Source="RINGGOLD">4919</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reynolds</LastName><ForeName>John A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-8962-4404</Identifier><AffiliationInfo><Affiliation>Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.</Affiliation><Identifier Source="RINGGOLD">1724</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology Department, City Hospital, Sandwell and West Birmingham NHS Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruce</LastName><ForeName>Ian N</ForeName><Initials>IN</Initials><Identifier Source="ORCID">0000-0003-3047-500X</Identifier><AffiliationInfo><Affiliation>The Kellgren Centre for Rheumatology, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.</Affiliation><Identifier Source="RINGGOLD">5293</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Musculoskeletal Research, The University of Manchester, Faculty of Biology Medicine and Health, Manchester Academic Health Science Centre, Manchester, UK.</Affiliation><Identifier Source="RINGGOLD">12203</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>International Collaborating Clinics Consortium</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>MASTERPLANS Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/M01665X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">clinical outcomes</Keyword><Keyword MajorTopicYN="N">disease activity</Keyword><Keyword MajorTopicYN="N">predictors</Keyword></KeywordList><CoiStatement>
<b>Competing Interests</b>
. <b>INB</b> has received grant support from GSK, Roche, Janssen, Astra Zeneca and UCB; consulting fees from AstraZeneca, Eli Lilly, GSK, Merck Serono and UCB; and was a speaker for AstraZeneca, GSK and UCB. <b>CG</b> has received personal fees for honoraria from consultancy work from the Centre for Disease Control, Astra-Zeneca, MGP, Sanofi and UCB, personal fees for speaker&#x2019;s bureau from UCB, and an educational grant from UCB to Sandwell and West Birmingham Hospitals NHS Trust that have supported her research work. <b>LS</b> has received personal fees for statistical consultation for Nemysis Ltd. <b>BP</b> has received personal fees for honoraria from Roche, Astra-Zeneca, Abbvie, GSK, UCB, Fesenius Kabi, Lilly. <b>YC:</b> nil. <b>TD:</b> nil. <b>JR</b>: nil. <b>DI</b>: nil</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>19</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>18</Day><Hour>21</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37463793</ArticleId><ArticleId IdType="mid">EMS181142</ArticleId><ArticleId IdType="pmc">PMC7614893</ArticleId><ArticleId IdType="doi">10.1177/09612033231183273</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003;82(5):299&#x2013;308. doi: 10.1097/01.md.0000091181.93122.55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.md.0000091181.93122.55</ArticleId><ArticleId IdType="pubmed">14530779</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev. 2004;3(6):423&#x2013;453. doi: 10.1016/j.autrev.2004.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2004.04.002</ArticleId><ArticleId IdType="pubmed">15351310</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016;12(10):605&#x2013;620. doi: 10.1038/nrrheum.2016.137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2016.137</ArticleId><ArticleId IdType="pubmed">27558659</ArticleId></ArticleIdList></Reference><Reference><Citation>Tektonidou MG, Lewandowski LB, Hu J, Dasgupta A, Ward MM. Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Ann Rheum Dis. 2017;76(12):2009&#x2013;2016. doi: 10.1136/annrheumdis-2017-211663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211663</ArticleId><ArticleId IdType="pubmed">28794077</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology. 2020;59(Supplement_5):v69&#x2013;v81. doi: 10.1093/rheumatology/keaa403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa403</ArticleId><ArticleId IdType="pmc">PMC7719039</ArticleId><ArticleId IdType="pubmed">33280011</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi: 10.1002/art.1780400928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. QJM An Int J Med. 1993;86(7):447&#x2013;458. doi: 10.1093/oxfordjournals.qjmed.a068841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.qjmed.a068841</ArticleId><ArticleId IdType="pubmed">8210301</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg DA, Gordon C BILAG Group. British Isles Lupus Assessment Group. From BILAG to BLIPS--disease activity assessment in lupus past, present and future. Lupus. 2000;9(9):651&#x2013;654. doi: 10.1191/096120300672904669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120300672904669</ArticleId><ArticleId IdType="pubmed">11199918</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Iba&#xf1;ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. [Accessed August 10, 2021];J Rheumatol. 2002 29(2):288&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy C-L, Yee C-S, Gordon C, Isenberg D. From BILAG to BILAG-based combined lupus assessment-30 years on. Rheumatology (Oxford) 2016;55(8):1357&#x2013;1363. doi: 10.1093/rheumatology/kev387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kev387</ArticleId><ArticleId IdType="pubmed">26589244</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies JC, Carlsson E, Midgley A, et al. A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment. Rheumatology (Oxford) 2021;60(8):3747&#x2013;3759. doi: 10.1093/rheumatology/keaa851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa851</ArticleId><ArticleId IdType="pmc">PMC8328509</ArticleId><ArticleId IdType="pubmed">33313921</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363&#x2013;369. doi: 10.1002/art.1780390303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780390303</ArticleId><ArticleId IdType="pubmed">8607884</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222&#x2013;233. doi: 10.1002/art.27233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27233</ArticleId><ArticleId IdType="pmc">PMC4548300</ArticleId><ArticleId IdType="pubmed">20039413</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanly JG, Li Q, Su L, et al. Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care Res (Hoboken) 2018;70(10):1478&#x2013;1487. doi: 10.1002/acr.23509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23509</ArticleId><ArticleId IdType="pmc">PMC6033693</ArticleId><ArticleId IdType="pubmed">29316357</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware J, Kosinski M. SF-36 physical &amp; mental health summary scales: a manual for users of version 1.  [Accessed August 10, 2021];2001  
 https://scholar.google.com/scholar?cluster=12170310011220991776&amp;hl=en&amp;as_sdt=2005&amp;sciodt=0,5
.</Citation></Reference><Reference><Citation>Tibshirani R. Regression Shrinkage and Selection via the lasso. J R Stat Soc B. 1996;58(1):267&#x2013;288.</Citation></Reference><Reference><Citation>Hastie T, Tibshirani R, Friedman JH. The elements of statistical learning: data mining, inference, and prediction. 2nd. New York: Springer; 2006.</Citation></Reference><Reference><Citation>Pirone C, Mendoza-Pinto C, van der Windt DA, Parker OB, Sullivan M, Bruce IN. Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review. Semin Arthritis Rheum. 2017;47(3):384&#x2013;396. doi: 10.1016/j.semarthrit.2017.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2017.04.010</ArticleId><ArticleId IdType="pmc">PMC5695978</ArticleId><ArticleId IdType="pubmed">28602359</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall&#x2019;Era M, Bruce IN, Gordon C, Manzi S, McCaffrey J, Lipsky PE. Current challenges in the development of new treatments for lupus. Ann Rheum Dis. 2019;78(6):729&#x2013;735. doi: 10.1136/annrheumdis-2018-214530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214530</ArticleId><ArticleId IdType="pubmed">30636212</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker B, Urowitz MB, Gladman DD, et al. Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis. 2015;74(8):1530&#x2013;1536. doi: 10.1136/annrheumdis-2013-203933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-203933</ArticleId><ArticleId IdType="pmc">PMC4515988</ArticleId><ArticleId IdType="pubmed">24692585</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce IN, O&#x2019;Keeffe AG, Farewell V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2015;74(9):1706&#x2013;1713. doi: 10.1136/annrheumdis-2013-205171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-205171</ArticleId><ArticleId IdType="pmc">PMC4552899</ArticleId><ArticleId IdType="pubmed">24834926</ArticleId></ArticleIdList></Reference><Reference><Citation>Parks CG, de Souza Espindola Santos A, Barbhaiya M, Costenbader KH. Understanding the role of environmental factors in the development of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017;31(3):306&#x2013;320. doi: 10.1016/J.BERH.2017.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.BERH.2017.09.005</ArticleId><ArticleId IdType="pmc">PMC5729939</ArticleId><ArticleId IdType="pubmed">29224673</ArticleId></ArticleIdList></Reference><Reference><Citation>Houssiau FA, D&#x2019;Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69(12):2083&#x2013;2089. doi: 10.1136/ard.2010.131995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.131995</ArticleId><ArticleId IdType="pmc">PMC3002764</ArticleId><ArticleId IdType="pubmed">20833738</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesar V, Hruskova Z. Lupus Nephritis: A Different Disease in European Patients? Kidney Dis (Basel, Switzerland) 2015;1(2):110&#x2013;118. doi: 10.1159/000438844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000438844</ArticleId><ArticleId IdType="pmc">PMC4934820</ArticleId><ArticleId IdType="pubmed">27536671</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Rovin BH, Houssiau F, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 2020;383(12):1117&#x2013;1128. doi: 10.1056/NEJMoa2001180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001180</ArticleId><ArticleId IdType="pubmed">32937045</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018;77(6):883&#x2013;889. doi: 10.1136/annrheumdis-2018-213032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-213032</ArticleId><ArticleId IdType="pubmed">29563108</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Manzi S, Aranow C, et al. Lupus community panel proposals for optimising clinical trials: 2018. Lupus Sci Med. 2018;5(1):e000258. doi: 10.1136/lupus-2018-000258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000258</ArticleId><ArticleId IdType="pmc">PMC5894527</ArticleId><ArticleId IdType="pubmed">29657738</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Urowitz MB. The SLICC/ACR damage index: progress report and experience in the field. Lupus. 1999;8(8):632&#x2013;637. doi: 10.1191/096120399680411335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120399680411335</ArticleId><ArticleId IdType="pubmed">10568900</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoll T, Sutcliffe N, Mach J, Klaghofer R, Isenberg DA. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus-a 5-yr prospective study. Rheumatology. 2004;43(8):1039&#x2013;1044. doi: 10.1093/rheumatology/keh238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keh238</ArticleId><ArticleId IdType="pubmed">15161983</ArticleId></ArticleIdList></Reference><Reference><Citation>Fessler BJ, Alarc&#xf3;n GS, McGwin G, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 2005;52(5):1473&#x2013;1480. doi: 10.1002/art.21039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21039</ArticleId><ArticleId IdType="pubmed">15880829</ArticleId></ArticleIdList></Reference><Reference><Citation>Hironari Hanaoka HL, et al.  Hydroxychloroquine Improves Disease Activity and Allows Reduction of Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus - ACR Meeting Abstracts.  [Accessed July 15, 2020]; 
 https://acrabstracts.org/abstract/hydroxychloroquine-improves-disease-activity-and-allows-reduction-of-corticosteroid-dose-regardless-of-background-treatment-in-japanese-patients-with-systemic-lupus-erythematosus/
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6543229</ArticleId><ArticleId IdType="pubmed">30626831</ArticleId></ArticleIdList></Reference><Reference><Citation>Aouhab Z, Hong H, Felicelli C, Tarplin S, Ostrowski RA. Outcomes of Systemic Lupus Erythematosus in Patients who Discontinue Hydroxychloroquine. ACR open Rheumatol. 2019;1(9):593&#x2013;599. doi: 10.1002/acr2.11084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11084</ArticleId><ArticleId IdType="pmc">PMC6857977</ArticleId><ArticleId IdType="pubmed">31777844</ArticleId></ArticleIdList></Reference><Reference><Citation>Konig Maximilian, Jessica Li MP. Hydroxychloroquine Blood Levels and Risk of Thrombotic Events in Systemic Lupus Erythematous - ACR Meeting Abstracts.  [Accessed July 15, 2020]; 
 https://acrabstracts.org/abstract/hydroxychloroquine-blood-levels-and-risk-ofthrombotic-events-in-systemic-lupus-erythematous/
</Citation></Reference><Reference><Citation>Alarc&#xf3;n GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) Ann Rheum Dis. 2007;66(9):1168&#x2013;1172. doi: 10.1136/ard.2006.068676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2006.068676</ArticleId><ArticleId IdType="pmc">PMC1955128</ArticleId><ArticleId IdType="pubmed">17389655</ArticleId></ArticleIdList></Reference><Reference><Citation>Kweon Seong-Min ACR, et al.  Compliance and Persistence with Hydroxychloroquine in Patients with Systemic Lupus Erythematosus - ACR Meeting Abstracts.  [Accessed July 28, 2020];2017  
 https://acrabstracts.org/abstract/compliance-and-persistence-with-hydroxychloroquine-in-patients-with-systemic-lupus-erythematosus/
</Citation></Reference><Reference><Citation>Costedoat-Chalumeau N, Houssiau F, Izmirly P, et al. A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. Clin Pharmacol Ther. 2018;103(6):1074&#x2013;1082. doi: 10.1002/cpt.885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.885</ArticleId><ArticleId IdType="pmc">PMC5858989</ArticleId><ArticleId IdType="pubmed">28925027</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu LH, Fevrier HB, Goldfien R, Hemmerling A, Herrinton LJ. Understanding Nonadherence with Hydroxychloroquine Therapy in Systemic Lupus Erythematosus. J Rheumatol. 2019;46(10):1309&#x2013;1315. doi: 10.3899/jrheum.180946.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.180946</ArticleId><ArticleId IdType="pubmed">30709949</ArticleId></ArticleIdList></Reference><Reference><Citation>Golder V, Kandane-Rathnayake R, Hoi AY-B, et al. Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. Arthritis Res Ther. 2016;18(1):260. doi: 10.1186/s13075-016-1163-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-016-1163-2</ArticleId><ArticleId IdType="pmc">PMC5103412</ArticleId><ArticleId IdType="pubmed">27829463</ArticleId></ArticleIdList></Reference><Reference><Citation>Tani C, Vagelli R, Stagnaro C, Carli L, Mosca M. Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort. Lupus Sci Med. 2018;5(1):e000234. doi: 10.1136/lupus-2017-000234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2017-000234</ArticleId><ArticleId IdType="pmc">PMC5844382</ArticleId><ArticleId IdType="pubmed">29531772</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, et al. Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort. J Rheumatol. 2019;46(10):1299&#x2013;1308. doi: 10.3899/jrheum.180433.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.180433</ArticleId><ArticleId IdType="pubmed">30824636</ArticleId></ArticleIdList></Reference><Reference><Citation>Babaoglu H, Li J, Goldman D, Magder LS, Petri M. Predictors of predominant Lupus Low Disease Activity State (LLDAS-50) Lupus. 2019;28(14):1648&#x2013;1655. doi: 10.1177/0961203319886028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319886028</ArticleId><ArticleId IdType="pmc">PMC6872940</ArticleId><ArticleId IdType="pubmed">31694446</ArticleId></ArticleIdList></Reference><Reference><Citation>Kallberg H, Jacobsen S, Bengtsson C, et al. Alcohol consumption is associated with decreased risk of rheumatoid arthritis: results from two Scandinavian case-control studies. Ann Rheum Dis. 2009;68:222&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2937278</ArticleId><ArticleId IdType="pubmed">18535114</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>